BioSpace News Archive

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that it will host a virtual investor event to present interim data from the first-in-human clinical studies of NTLA-2002 and NTLA-2001 on September 16, 2022, at 8:00 a.m. ET.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the H.C. Wainwright 24th Annual Global Investment Conference.

via NewMediaWire – Nephros, Inc., a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, announced the appointment of Joe Harris to its Board of Directors.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming H.C. Wainwright Global Investment Conference in New York, New York.

Dynavax Technologies Corporation (Nasdaq: DVAX), today announced that Ryan Spencer, Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12-14, 2022.

Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that management will participate at the following investor conferences.

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that the management team will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference at 1:30 p.m. ET as well as in one-on-one meetings in New York City on Wednesday, September 14, 2022.

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acorda’s President and Chief Executive Officer, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12 at 3 p.m. ET.

Catalent, Inc. announced that members of its executive leadership team will participate at two upcoming investor conferences.

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2022.